Press releases

Quantum Genomics to Present at Biotech Showcase 2019

Quantum Genomics to Host Key Opinion Leader and Investor Event on December 10, 2018

Quantum Genomics Announces Excellent Topline Results from Phase 2b NEW-HOPE Study Evaluating Firibastat for Arterial Hypertension

Quantum Genomics Announces Webcast Discussion of Top-line Results from its Phase 2b NEW-HOPE Study in Arterial Hypertension on November 12, 2018

Quantum Genomics receives ethics committee approval to initiate clinical study of extended-release firibastat tablets

Quantum Genomics to Present Top-Line Results from Phase 2b NEW-HOPE Study in Late-Breaking Presentation on November 10, 2018, at the American Heart Association meeting in Chicago

Quantum Genomics Reports First Half Financial Results and Provides Corporate Update

Quantum Genomics will present top line results for the NEW HOPE phase IIb hypertension study at the American Heart Association (AHA) annual meeting in Chicago (November 10-12, 2018)

Quantum Genomics completes patient recruitment more than six months ahead of initial schedule in its phase IIb hypertension (NEW-HOPE) study, now expects to present results by mid-November 2018

Quantum Genomics announces trial design for QUORUM, its Phase IIb study in heart failure

FIRIBASTAT Approved as Common International Name for QGC001 by World Health Organization

Quantum Genomics enters a new phase of maturity with its BAPAIs Fast Growth strategic plan

Quantum Genomics strengthens its governance

Quantum Genomics publishes its financial results for the year 2017

Quantum Genomics Secures Operational Flexibility and Growth Capital through Equity Line Financing with Kepler Cheuvreux

Quantum Genomics strengthens its Scientific Advisory Board with the appointment of Professor Frans Leenen, a renowned expert in congestive heart failure